Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07275736 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 15, 2025 to Mar 1, 2025
    v3
  2. Start date: Nov 29, 2025 to Dec 15, 2025
    • Secondary endpoints: 10 to 11
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Trial Details
NCT Number NCT07275736
Lead Sponsor Juventas Cell Therapy Ltd.
Collaborators: Beijing Tiantan Hospital
Conditions
(from sponsor)		 Neurological Autoimmune Diseases
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov